fda warning letters compounded semaglutide september 2025 COMES FOR NOVO DRAMA. #medicine #wellness #news #life #hospital FDA Targets GLP-1 and Peptide

The article says the decision involves more than age or weight: providers typically evaluate BMI status, obesity-related complications, documented metabolic dysfunction, cardiovascular risk, previous weight-loss interventions, and family history of metabolic disease

Participation from drug manufacturers and health plans remains voluntary, but the initiative signals a clear policy shift

If you're in your 40s (sometimes late 30s) and experiencing these symptoms, you're likely in perimenopause

When you are eating, GLP-1 sends the brain the Im full signal

An empty laundry detergent bottle or bleach bottle works perfectly

More broadly, a narrative review in the journal Dermatology & Therapy bottled the issue by calling vitamin & mineral supplementation a clear modifiable risk factor for hair loss